{"title": "PPT - Vacunas e inmunoterapias PowerPoint Presentation, free download - ID:967901", "author": "Kiet", "url": "https://www.slideserve.com/kiet/vacunas-e-inmunoterapias", "hostname": "slideserve.com", "description": "Vacunas e inmunoterapias. Alejandro Chabalgoity Desarrollo Biotecnol \u00f3gico Instituto de Higiene \u2013 Facultad de Medicina. Muchos pat\u00f3genos han desarrollado mecanismos que le permiten evadir la respuesta inmune y no pueden ser eliminados en forma natural: importancia de las vacunas.", "sitename": "SlideServe", "date": "2012-11-24", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "620 likes | 1.08k Views\nVacunas e inmunoterapias. Alejandro Chabalgoity Desarrollo Biotecnol \u00f3gico Instituto de Higiene \u2013 Facultad de Medicina. Muchos pat\u00f3genos han desarrollado mecanismos que le permiten evadir la respuesta inmune y no pueden ser eliminados en forma natural: importancia de las vacunas.\nE N D\n[Vacunas e inmunoterapias](https://image.slideserve.com/967901/vacunas-e-inmunoterapias-l.jpg) Alejandro Chabalgoity Desarrollo Biotecnol\u00f3gico Instituto de Higiene \u2013 Facultad de Medicina [Muchos pat\u00f3genos han desarrollado mecanismos que le](https://image.slideserve.com/967901/slide2-l.jpg) permiten evadir la respuesta inmune y no pueden ser eliminados en forma natural:importancia de las vacunas [La utilizaci\u00f3n masiva de las vacunas disponibles, en su](https://image.slideserve.com/967901/slide3-l.jpg) mayor\u00eda desarrolladas emp\u00edricamente, ha tenido un enorme impacto en salud humana, s\u00f3lo superado por la disponibilidad de agua potable [ Vaccines have been the greatest achievement of biomedical](https://image.slideserve.com/967901/slide4-l.jpg) sciences. Their impact in public health is only exceeded by the availability of potable water [ Vaccines have been the greatest achievement of biomedical](https://image.slideserve.com/967901/slide5-l.jpg) sciences. Their impact in public health is only exceeded by the availability of potable water [Cronograma de aparici\u00f3n de las principales vacunas ](https://image.slideserve.com/967901/slide6-l.jpg) de uso humano: - 1796: Vacunaci\u00f3n contra la viruela - 1885: Vacuna contra la rabia - 1925: Toxoide dift\u00e9rico, Toxoide tet\u00e1nico y tos combulsa - 1937: Vacuna contra la fiebre amarilla - 1943: Vacuna contra influenza - 1954: Vacuna inactivada contra virus de la polio - 1956: Vacuna viva atenuada contra virus de la polio - 1960: Vacuna contra el sarampi\u00f3n - 1966: Vacuna contra la rube\u00f3la - 1975: Vacuna contra hepatitis B - 1980: Viruela erradicada - 1986: Primera vacuna recombinante (hepatitis B) - 1988: Vacuna conjugada contra H. influenzae B [Incidencia pre- y post- vacunaci\u00f3n de las enfermedades](https://image.slideserve.com/967901/incidencia-pre-y-post-vacunaci-n-de-las-enfermedades-prevenibles-l.jpg) prevenibles. [\u00bf Qu\u00e9 hace posible la vacunaci\u00f3n?](https://image.slideserve.com/967901/qu-hace-posible-la-vacunaci-n-l.jpg) Dos propiedades fundamentales de la inmunidad adquirida: * Especificidad * Memoria [\u00bfQue caracter\u00edsticas debe tener?](https://image.slideserve.com/967901/que-caracter-sticas-debe-tener-l.jpg) \u2022 - Segura \u2022 - Evita la enfermedad \u2022 - Protege a una proporci\u00f3n alta de quienes la reciben \u2022 - Induce protecci\u00f3n duradera \u2022 - Carece de efectos secundarios \u2022 - Estable \u2022 - Bajo costo por dosis [\u00bfQue tipos de vacunas existen?](https://image.slideserve.com/967901/que-tipos-de-vacunas-existen-l.jpg) \u2022 Tradicionalmente, se han utilizado: \u2022 Microorganismos vivos atenuados emp\u00edricamente, patogenos de otras especies \u2022 Microorganismos muertos \u2022 Ant\u00edgenos purificados (\"subunidades\") \u2022 Prote\u00ednas o polisac\u00e1ridos del pat\u00f3geno \u2022 * Virus \u2022 Ag de superficie (Hepatitis B: HBsAg) \u2022 * Bacterias \u2022 - Polisac\u00e1ridos capsulares (ej: neumo y meningo) \u2022 - Exotoxinas modificadas (Toxoide tet\u00e1nico) [Impacto del uso de vacunas](https://image.slideserve.com/967901/impacto-del-uso-de-vacunas-l.jpg) \u2022 La utilizaci\u00f3n masiva de las vacunas tradicionales \u2022 (desarrolladas emp\u00edricamente): \u2022 Ha tenido un impacto enorme en salud humana, modificando sustancialmente la expectativa de vida de la poblaci\u00f3n \u2022 Ha permitido el control de pat\u00f3genos: - causantes de infecciones agudas, que generan inmunidad \u2022 duradera \u2022 carentes de variaci\u00f3n antig\u00e9nica \u2022 para los que existen modelos experimentales [VACUNAS](https://image.slideserve.com/967901/slide14-l.jpg) SISTEMATICAS NO SISTEMATICAS Dr. Jorge Quian MSP - 2008 [VACUNAS](https://image.slideserve.com/967901/slide15-l.jpg) SISTEMATICAS Dr. Jorge Quian MSP - 2008 [VACUNAS](https://image.slideserve.com/967901/slide17-l.jpg) NO SISTEMATICAS Antimeningoc\u00f3ccica Antipapilomavirus Antigripal Dr. Jorge Quian MSP - 2008 [Sin embargo:](https://image.slideserve.com/967901/sin-embargo-l.jpg) \u2022 Las enfermedades infecciosas siguen siendo el \u2022 principal problema de salud humana (y animal) en el mundo \u2022 Algunos pat\u00f3genos para las que existen vacunas, mantienen \u2022 alta morbi/mortalidad, y no es posible una cobertura global \u2022 con las vacunas actuales (inmunidad no duradera, vacuna inestable) \u2022 Existen situaciones en las que el principio cl\u00e1sico de vacunaci\u00f3n no es aplicable (respuesta inmune d\u00e9bil, o no efectiva) \u2022 Necesidad de vacunas terap\u00e9uticas; (HSV, cancer) [Situaci\u00f3n actual](https://image.slideserve.com/967901/situaci-n-actual-l.jpg) En los \u00faltimos a\u00f1os se ha producido un avance espectacular en el dise\u00f1o de nuevas vacunas comoresultado de: \u2022 incremento en el conocimiento de c\u00f3mo los \u2022 pat\u00f3genos causan enfermedad - avance en el conocimiento de la inmunolog\u00eda de las infecciones \u2022 avances tecnol\u00f3gicos: ADN recombinante, \u2022 an\u00e1lisis masivo de informaci\u00f3n gen\u00e9tica, etc. [Why can\u2019t we go on with the same approach used for classic](https://image.slideserve.com/967901/why-can-t-we-go-on-with-the-same-approach-used-for-classic-vaccines-to-develop-new-ones-l.jpg) vaccines to develop new ones? \u2022 First encounter may not result in protective immunity \u2022 Classical approach may elicit immunopathology \u2022 We may need vaccinate people already infected [Estrategias de desarrollo](https://image.slideserve.com/967901/estrategias-de-desarrollo-l.jpg) Dirigidas a: \u2022 Generar una respuesta inmune mas efectiva contra cada pat\u00f3geno en particular \u2022 Localizaci\u00f3n de la RI (sist\u00e9mica vs. mucosas) [Vacunas de mucosas](https://image.slideserve.com/967901/vacunas-de-mucosas-l.jpg) \u2022 La mayor\u00eda de los pat\u00f3genos ingresas por mucosas: respuesta localizada la mas efectiva \u2022 Ags adminstrados por v\u00eda sist\u00e9mica no generan RIM \u2022 Estrategias para generar RIM \u2022 Uso de vectores vivos (principalmente bacterias) \u2022 Uso de prote\u00ednas derivadas de pat\u00f3genos con propiedad adyuante (toxina col\u00e9rica, toxina termolabil de E.coli, flagelina, etc.) [Salmonella enterica as a vector for new vaccines and](https://image.slideserve.com/967901/salmonella-enterica-as-a-vector-for-new-vaccines-and-immunotherapies-l.jpg) immunotherapies [The development of live Salmonellae into a delivery system](https://image.slideserve.com/967901/the-development-of-live-salmonellae-into-a-delivery-system-for-oral-vaccines-l.jpg) for oral vaccines \u2022 Live attenuated Salmonellae can be prepared by defined mutations into the chromosome \u2022 Can be administered orally; persist in the tissues for a limited period of time stimulating strong immune responses \u2022 Engineered to express heterologous antigens Can elicit protective responses after a single dose \u2022 It has a very good record of safety use, as demonstrated in phase I and phase II clinical trials [Mucosal vaccination delays or prevents prion infection via](https://image.slideserve.com/967901/slide29-l.jpg) an oral route Goni et alNeuroscience (2005) Patent: WO 2005/019412. A2. PCT/US2004/016242. 20 May 2004 [A Dog-Adapted Salmonella typhimurium Strain as a Basis for a](https://image.slideserve.com/967901/slide30-l.jpg) Live Oral Echinococcus granulosus vaccine Chabalgoity et alVaccine (2000) An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease Petavy et al PLos Neglected Pathogens (2008) Patent submitted in France: No. 06 50799, 8 de Marzo 2006 [Intranasal immunization with flagellin stimulate TL5](https://image.slideserve.com/967901/intranasal-immunization-with-flagellin-stimulate-tl5-expression-in-cln-and-spleen-l.jpg) expression in CLN and spleen [Estrategias de desarrollo](https://image.slideserve.com/967901/estrategias-de-desarrollo1-l.jpg) Dirigidas a: \u2022 Generar una respuesta inmune mas efectiva contra cada pat\u00f3geno en particular \u2022 Localizaci\u00f3n de la RI (sist\u00e9mica vs. mucosas) \u2022 Generaci\u00f3n adecuada de memoria inmunol\u00f3gica (vacunas conjugadas) [Estrategias de desarrollo](https://image.slideserve.com/967901/estrategias-de-desarrollo2-l.jpg) Dirigidas a: \u2022 Generar una respuesta inmune mas efectiva contra cada pat\u00f3geno en particular \u2022 Localizaci\u00f3n de la RI (sist\u00e9mica vs. mucosas) \u2022 Generaci\u00f3n adecuada de memoria inmunol\u00f3gica (vacunas conjugadas) \u2022 Mejorar el tipo de mecanismos efectores generados (vacunas a ADN) [Vacunas g\u00e9nicas](https://image.slideserve.com/967901/vacunas-g-nicas-l.jpg) \u2022 Muy seguras \u2022 Efectivas en modelos experimentales \u2022 F\u00e1cil producci\u00f3n y escalado \u2022 Generan mecanismos efectores especiales [Vacunas g\u00e9nicas](https://image.slideserve.com/967901/vacunas-g-nicas1-l.jpg) \u2022 Muy seguras \u2022 Generan mecanismos efectores especiales \u2022 F\u00e1cil producci\u00f3n y escalado \u2022 Efectivas en modelos experimentales \u2022 En cl\u00ednica RI en general d\u00e9biles Necesidad de mejorar su potencia - adyuvantes moleculares - pistola g\u00e9nica, inmunizaci\u00f3n cut\u00e1nea - vectores vivos [Adjuvantes moleculares (agonistas de TLR, CpG, citoquinas,](https://image.slideserve.com/967901/adjuvantes-moleculares-agonistas-de-tlr-cpg-citoquinas-etc-l.jpg) etc.) [Gene-gun para](https://image.slideserve.com/967901/slide41-l.jpg) Vacunas a ADN Inmunizaci\u00f3n transcut\u00e1nea [Vacunas a DNA portadas por bacterias atenuadas](https://image.slideserve.com/967901/vacunas-a-dna-portadas-por-bacterias-atenuadas-l.jpg) MHC class I \u00f3 II ? Nucleus APC [Learning from successful vaccines\u2026 ](https://image.slideserve.com/967901/learning-from-successful-vaccines-l.jpg) J Exp Med. 2006 Vol. 203: 413\u2013424 [YF-17D activates DCs through multiple TLRs and multiple TLR](https://image.slideserve.com/967901/yf-17d-activates-dcs-through-multiple-tlrs-and-multiple-tlr-adaptor-proteins-l.jpg) adaptor proteins. J Exp Med. 2006 Vol. 203: 413\u2013424 Lack of a single TLR depletes IL-12 and IL-6 production [The lessons\u2026](https://image.slideserve.com/967901/the-lessons-l.jpg) \u2022 Future vaccinologists should not only concern themselves with using the right combination of adjuvants but also having vaccine preparations that are \u201cclean,\u201d but which recapitulate the immunogenicity of the \u201cdirty\u201d vaccines [Estrategias de desarrollo](https://image.slideserve.com/967901/estrategias-de-desarrollo3-l.jpg) Dirigidas a: \u2022 Generar una respuesta inmune mas efectiva contra cada pat\u00f3geno en particular \u2022 Localizaci\u00f3n de la RI (sist\u00e9mica vs. mucosas) \u2022 Generaci\u00f3n adecuada de memoria inmunol\u00f3gica (vacunas conjugadas) \u2022 Mejorar el tipo de mecanismos efectores generados (adyuvantes moleculares, co-administraci\u00f3n de citoquinas, vacunas a ADN) \u2022 Potenciar respuestas naturalmente d\u00e9biles (c\u00e1ncer) [Vacunas para c\u00e1ncer:Modificaci\u00f3n ex vivo de C\u00e9lulas](https://image.slideserve.com/967901/slide48-l.jpg) dendr\u00edticas [Towards new Immunotherapies:Targeting recombinant cytokines](https://image.slideserve.com/967901/slide49-l.jpg) to the immune system using live attenuated Salmonella", "language": null, "image": "https://cdn0.slideserve.com/967901/vacunas-e-inmunoterapias-n.jpg", "pagetype": "article", "links": ["\\", "#", "/presentations", "/presentations", "/topics", "/updates", "/featured", "/powerpoint-templates", "/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/article-stories", "/online-survey", "/online-quiz", "/lead-generation", "/create?type=ebook&utm_source=slideserve&utm_medium=website&utm_campaign=ebook+creator", "https://www.slideserve.com/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/pro", "/upload", "/kiet", "https://image.slideserve.com/967901/vacunas-e-inmunoterapias-l.jpg", "https://image.slideserve.com/967901/slide2-l.jpg", "https://image.slideserve.com/967901/slide3-l.jpg", "https://image.slideserve.com/967901/slide4-l.jpg", "https://image.slideserve.com/967901/slide5-l.jpg", "https://image.slideserve.com/967901/slide6-l.jpg", "https://image.slideserve.com/967901/incidencia-pre-y-post-vacunaci-n-de-las-enfermedades-prevenibles-l.jpg", "https://image.slideserve.com/967901/qu-hace-posible-la-vacunaci-n-l.jpg", "https://image.slideserve.com/967901/que-caracter-sticas-debe-tener-l.jpg", "https://image.slideserve.com/967901/que-tipos-de-vacunas-existen-l.jpg", "https://image.slideserve.com/967901/slide12-l.jpg", "https://image.slideserve.com/967901/impacto-del-uso-de-vacunas-l.jpg", "https://image.slideserve.com/967901/slide14-l.jpg", "https://image.slideserve.com/967901/slide15-l.jpg", "https://image.slideserve.com/967901/slide17-l.jpg", "https://image.slideserve.com/967901/recommended-childhood-immunization-schedule-in-u-s-a-2001-l.jpg", "https://image.slideserve.com/967901/sin-embargo-l.jpg", "https://image.slideserve.com/967901/es-necesario-contar-con-nuevas-y-mas-eficaces-vacunas-l.jpg", "https://image.slideserve.com/967901/situaci-n-actual-l.jpg", "https://image.slideserve.com/967901/why-can-t-we-go-on-with-the-same-approach-used-for-classic-vaccines-to-develop-new-ones-l.jpg", "https://image.slideserve.com/967901/dise-o-racional-de-nuevas-vacunas-e-inmunoterapias-l.jpg", "https://image.slideserve.com/967901/estrategias-de-desarrollo-l.jpg", "https://image.slideserve.com/967901/vacunas-de-mucosas-l.jpg", "https://image.slideserve.com/967901/salmonella-enterica-as-a-vector-for-new-vaccines-and-immunotherapies-l.jpg", "https://image.slideserve.com/967901/the-development-of-live-salmonellae-into-a-delivery-system-for-oral-vaccines-l.jpg", "https://image.slideserve.com/967901/slide29-l.jpg", "https://image.slideserve.com/967901/slide30-l.jpg", "https://image.slideserve.com/967901/flagellin-as-mucosal-adjuvant-l.jpg", "https://image.slideserve.com/967901/flagellin-a-mucosal-adjuvant-l.jpg", "https://image.slideserve.com/967901/intranasal-immunization-with-flagellin-stimulate-tl5-expression-in-cln-and-spleen-l.jpg", "https://image.slideserve.com/967901/estrategias-de-desarrollo1-l.jpg", "https://image.slideserve.com/967901/vacunas-conjugadas-l.jpg", "https://image.slideserve.com/967901/estrategias-de-desarrollo2-l.jpg", "https://image.slideserve.com/967901/vacunas-g-nicas-l.jpg", "https://image.slideserve.com/967901/vacunas-g-nicas-dna-vaccines-l.jpg", "https://image.slideserve.com/967901/vacunas-g-nicas1-l.jpg", "https://image.slideserve.com/967901/adjuvantes-moleculares-agonistas-de-tlr-cpg-citoquinas-etc-l.jpg", "https://image.slideserve.com/967901/slide41-l.jpg", "https://image.slideserve.com/967901/vacunas-a-dna-portadas-por-bacterias-atenuadas-l.jpg", "https://image.slideserve.com/967901/learning-from-successful-vaccines-l.jpg", "https://image.slideserve.com/967901/yf-17d-activates-dcs-through-multiple-tlrs-and-multiple-tlr-adaptor-proteins-l.jpg", "https://image.slideserve.com/967901/the-lessons-l.jpg", "https://image.slideserve.com/967901/estrategias-de-desarrollo3-l.jpg", "https://image.slideserve.com/967901/vacunas-para-c-ncer-c-lulas-tumorales-modificadas-l.jpg", "https://image.slideserve.com/967901/slide48-l.jpg", "https://image.slideserve.com/967901/slide49-l.jpg", "https://image.slideserve.com/967901/salmonella-accumulates-inside-solid-tumors-l.jpg", "/martaacevedo/virus-y-vacunas-informaticos", "/johana/vacunas-recombinantes", "/orli/vacunas", "/trina/vacunas-en-equinos-powerpoint-ppt-presentation", "/arkadiy/vacunas-en-el-enfermo-renal", "/ethel/producci-n-p-blica-de-vacunas-1346081", "/kamran/los-bichos-de-las-vacunas", "/jace/las-vacunas", "/quasim/vacunas", "/yorick/vacunas-en-la-infancia", "/barton/vacunas-gen-ticas", "/vanig/vacunas-pand-micas-antigripales-h5n1", "/china/vacunas-aprobadas-por-fda-2005", "/milt/aseguramiento-de-la-calidad-vacunas", "/xenos/actualizaci-n-en-vacunas-nivel-i", "/miller/vacunas", "/emlyn/vacunas-y-vacunaci-n-en-bovinos", "/gallia/las-vacunas-evoluci-n-de-actividades", "/jara/alergias-y-vacunas", "/lassie/region-de-salud-programa-de-vacunas-e-inmunizaciones", "/rhoslyn-bronwen/qu-nos-acultan-las-vacunas", "/noel-puckett/taller-de-vacunas", "//www.slideserve.com", "//fr.slideserve.com", "/about", "/privacy", "/dmca", "https://blog.slideserve.com", "/contact", "https://www.facebook.com/SlideServe", "https://twitter.com/slideserve", "https://www.youtube.com/user/SlideServe", "https://www.pinterest.com/slideserve/"]}